Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience ...

The Centers for Medicare & Medicaid Services announced Nov. 25 that Medicare recipients will pay less for 15 prescription ...

As the US Centers for Medicare and Medicaid Services (CMS) has released the new prices for 15 drugs that have been added to ...

The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate ...

The Medicare health plan said on Tuesday that newly negotiated prices for 15 of its costliest drugs will save 36% on those ...

CMS announces billions in savings for Medicare when first and second rounds of negotiations go into effect in 2026 and 2027, ...

AbbVie has a strong presence in immunology, oncology and neuroscience areas. Other than that, AbbVie also has products for ...

Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

Medicare officials on November 25 unveiled the negotiated prices for 15 of the program’s most expensive drugs, anticipating ...

Pfizer possesses several qualities that make it attractive when market volatility is high. The stock has a low forward earnings multiple and a higher -- yet still attractive -- EV-to-EBITDA ratio.

Medicare health plan, a potential signal of the Trump administration's commitment to bring ​down healthcare costs. The ...

Discover why Pfizer stock may be set for a bull run by 2026 with key wins, strong Q3 earnings, and growth drivers.